Placebo-adjusted reductions in endoscopic nasal polyp score reached -1.95 (p < 0.0001) at Week 24 under a worst-observation carried-forward analysis that penalized rescue use, compared with -1.77 (p < 0.0001) in the trial’s primary treatment-policy analysis. Nasal congestion score improved by -0.96 (p < 0.0001) with the rescue-adjusted approach versus -0.77 (p = 0.0003) in the primary analysis. Verekitug also cut surgery or systemic corticosteroid interventions by 76% (p = 0.03). The 24-week Phase 2 study enrolled 81 adults with chronic rhinosinusitis with nasal polyps (CRSwNP) on background intranasal corticosteroids and dosed verekitug 100 mg subcutaneously every 12 weeks, with no serious adverse events reported. The news is an additional analysis cut from the Phase 2 VIBRANT trial, presented as a late breaker and framed to align with contemporary estimand practice in CRSwNP by adjusting for concomitant rescue therapies, including surgery and systemic steroids. Upstream Bio is positioning these data as confirmatory to prior top-line results and as groundwork for registrational development. Phase 3 planning is underway in both CRSwNP and severe asthma, extending a strategy that pursues the well-documented overlap between upper and lower airway inflammation. Methodologically, the shift to a WOCF framework highlights a choice to emphasize clinical control that discourages rescue use, a metric that payers and regulators increasingly scrutinize in sinonasal disease given the cost and morbidity of repeat surgery and systemic steroid exposure. It also seeks cleaner cross-trial comparability with recent biologic programs that have incorporated failure-handling for rescue events. Strategically, Upstream is leaning on two potential differentiators: a 12-week dosing interval that reduces on-site burden relative to several approved CRSwNP biologics, and a receptor-targeting approach to TSLP signaling distinct from ligand-binding pathways. The company’s parallel path in severe asthma creates an efficiency narrative around a single mechanism addressing comorbid populations, but it also concentrates clinical and operational risk into one asset. For sites and CROs, a q12-week regimen combined with endoscopic outcomes favors tighter visit consolidation but raises operational emphasis on standardized endoscopy capture, blinded central reads, and rigorous adjudication of rescue triggers. Rescue-minimizing designs can simplify patient journeys but require clear, prospectively enforced criteria to avoid site-to-site variability that can erode effect estimates. Vendors supporting ePRO for congestion scoring and image management will be central to Phase 3 execution. Sponsors watching the category will note the explicit bid to make reductions in surgical and steroid interventions a cornerstone outcome, a lever that can resonate with HTAs and payers if replicated at scale. Regulators will look for consistency across subgroups, durability beyond 24 weeks, and clarity on estimands that reconcile treatment-policy and rescue-adjusted interpretations. Next, attention shifts to Phase 3 protocol details: co-primary endpoints and weighting, handling of rescue and surgery, inclusion of patients with prior biologic exposure, and the duration needed to demonstrate sustained polyp control and symptom relief. With small-n Phase 2 data, the true safety and immunogenicity profile remains to be defined over longer exposure and in more heterogeneous populations. Competitive benchmarks in CRSwNP are rising, including programs that have recently read out on similar endpoints, so network meta-analyses will likely shape early positioning absent head-to-head comparisons. The operational upside of q12-week dosing is meaningful, but manufacturing scale, device reliability, and site training will need to keep pace if Upstream intends to run concurrent registrational studies across airway indications.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
FDA Clears IND for Umoja’s UB-VV400 In Vivo CAR T Therapy
2 months ago[…] the patient population it is designed to serve. CD22 is a well-validated B cell antigen, and the VIBRANT-1 Phase 1/2 trial explicitly includes patients who have already progressed after prior CAR T cell […]
Comments are closed.